Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Twice-Daily Poziotinib Improves Efficacy, Tolerability in EGFR- or HER2 Exon 20–Positive NSCLC

April 12th 2021

Administering the investigational TKI poziotinib at a twice-daily dose compared with once-daily dosing showed a reduction in both grade 3 or higher treatment emergent adverse effects and dose interruptions, as well as improved efficacy in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

CNS Response to MET Inhibition in NSCLC

April 12th 2021

The significance of using MET inhibitors to manage patients who have MET exon 14 skipping mutations in non–small cell lung cancer with CNS (central nervous system) involvement.

Tepotinib for MET Exon 14 Skipping Mutations in NSCLC

April 12th 2021

Implications for treating patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations with tepotinib, a MET inhibitor, based on data revealed by the VISION trial.

Undetectable METex14 Following Savolitinib Is Associated with Higher PFS, OS in NSCLC

April 11th 2021

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

Zenocutuzumab Demonstrates Efficacy in Blocking Growth of NRG1 Fusion–Driven Tumors

April 10th 2021

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

Dr. Le on the Safety of Twice-Daily Poziotinib in EGFR- or HER2 Exon 20–Positive NSCLC

April 10th 2021

Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

April 10th 2021

Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Neoadjuvant Nivolumab/Chemo Improves pCR in Resectable NSCLC

April 10th 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Liquid Biopsies and Molecular Testing in NSCLC

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the significance of molecular testing in clinical practice and the evolution of liquid biopsies in lung cancer treatment.

Meeting MET-Amplified NSCLC With Progress

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss promising agents in the treatment of patients with non–small cell lung cancer with MET amplification.

What's Happening in KRAS G12C+ NSCLC?

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the latest findings in KRAS G12C–positive non–small cell lung cancer.

Updates in EGFR+ NSCLC, Including Uncommon EGFR Mutations

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss data from the IASLC 2020 World Conference on Lung Cancer focused on EGFR-positive non–small cell lung cancer.

HER2-Directed Advances in Lung Cancer

April 9th 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Investigators Launch Epidemiology Study in Younger Patients With NSCLC

April 9th 2021

Investigators have launched the Epidemiology of Young Lung Cancer study to identify risk factors that can help shed light on why lung cancer develops in the younger population.

FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer

April 8th 2021

Dr. Weiss discusses the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.

Dr. Garon on Immunotherapy Treatment Considerations in NSCLC

April 8th 2021

Edward B. Garon, MD, discusses immunotherapy treatment considerations for patients with non–small cell lung cancer.

Lurbinectedin Approval Ignites a Spark for Precision Medicine in Small Cell Lung Cancer

April 7th 2021

Nisha A. Mohindra, MD, discusses the integration of lurbinectedin into the small cell lung cancer paradigm and remaining questions regarding future therapeutic directions.

Capmatinib for MET Exon 14-Mutated NSCLC

April 5th 2021

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Testing to Identify MET Exon 14 Mutations in NSCLC

April 5th 2021

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.